Early evidence suggested that this serum IL-6, IL-8, IL-1β, and TNF-α cytokine signature also predicts the prognosis of patients with acute COVID-19 (6), and targeting the IL-6 pathway seems an effective therapeutic strategy in critically ill COVID-19 patients (35, 36). The gene discussed is IL1B; the disease is COVID-19.